Bone Cancer: Bone Sarcomas and Bone Metastases - From Bench to Bedside, Third Edition comprehensively investigates key discoveries in the field of bone biology. New aspects of bone cancer biology are treated in new chapters covering exosomes, autophagy, and metabolism. These have led to the development of entirely new areas for investigation, such as therapies which combine surgery and biological approaches.
The Third Edition expands on the original overview of bone cancer development (physiology and pathophysiology), with 40% new material. Each chapter has been written by internationally recognized specialists on the bone cancer microenvironment, bone metastases, osteoclast biology in bone cancer, proteomics, bone niche, circulating tumor cells, and clinical trials.
Given the global prevalence of breast and prostate cancers, knowledge of bone biology has become essential for everyone within the medical and cancer research communities. Bone Cancer: Bone Sarcomas and Bone Metastases - From Bench to Bedside continues to offer the only translational reference to cover all aspects of primary bone cancer and bone metastases. This revision opens the door to myeloma with two short chapters dedicated to this bone-associated disease.
1. Bone Cancer - p. iii 2. Cover - p. iii 3. Title Page - p. iii 4. Copyright Page - p. iv 5. Table of Contents - p. iv 6. Contributors - p. xvii 7. Foreword I - p. xxiii 8. Foreword II - p. xxv 9. Foreword III - p. xxvii 10. Preface - p. xxix 11. Chapter 1 Cancer - p. 5 12. Chapter 2 Epidemiology of primary bone tumors and economical aspects of bone metastases - p. 17 13. Chapter 3 Mammalian models of bone sarcomas - p. 27 14. Chapter 4 In vivo models used in studies of bone metastases - p. 35 15. Chapter 5 Zebrafish models for studying bone tumors - p. 55 16. Chapter 6 Use of machine learning in bone cancers - p. 67 17. Chapter 7 Artificial intelligence for bone cancer imaging - p. 75 18. Chapter 8 Technical aspects - p. 93 19. Chapter 9 Bone niche and bone metastases - p. 107 20. Chapter 10 Bone, a fertile soil for tumor development - p. 121 21. Chapter 11 Osteomimicry - p. 129 22. Chapter 12 The role of mesenchymal stem cells in bone cancer - p. 145 23. Chapter 13 Technical approaches for studying the communications between osteocytes and cancer cells - p. 157 24. Chapter 14 Osteocytes and bone tumor niche - p. 171 25. Chapter 15 Immune functions of osteoclasts - p. 179 26. Chapter 16 The immune environment of bone sarcomas - p. 189 27. Chapter 17 Macrophages and pathophysiology of bone cancers - p. 205 28. Chapter 18 Growth factors, cytokines, and pediatric malignant primary bones tumors - p. 221 29. Chapter 19 Effects of NF-κB manipulation on cancer-associated bone disease - p. 241 30. Chapter 20 Transforming growth factor-β and its signaling pathway in skeletal complications of malignancy - p. 253 31. Chapter 21 Extracellular vesicles, tumor growth, and the metastatic process - p. 275 32. Chapter 22 Connexin43 and development of primary bone tumors - p. 285 33. Chapter 23 Role of classical cannabinoid receptors in cancer-associated bone disease - p. 295 34. Chapter 24 Impact of the acid microenvironment on bone cancers - p. 305 35. Chapter 25 Hypoxia-inducible factor (HIF)–mediated effects of the hypoxic niche in bone cancer - p. 321 36. Chapter 26 Energy metabolism in bone tumors - p. 337 37. Chapter 27 EMT process in bone metastasis - p. 359 38. Chapter 28 Cancer stem cells and clonal evolution in bone sarcomas - p. 371 39. Chapter 29 Dormancy in cancer bone metastasis - p. 393 40. Chapter 30 Bone remodeling markers and bone cancer - p. 413 41. Chapter 31 Epigenetic heterogeneity in primary bone cancers - p. 431 42. Chapter 32 MicroRNA implication in therapeutic resistance and metastatic dissemination of bone-associated tumors - p. 447 43. Chapter 33 MicroRNAs and bone metastasis - p. 457 44. Chapter 34 Long noncoding RNA and bone sarcoma - p. 471 45. Chapter 35 Liquid biopsy in bone sarcomas and identification of new biomarkers - p. 487 46. Chapter 36 Disseminated tumor cells in bone marrow of cancer patients - p. 501 47. Chapter 37 Cytogenetics of bone tumors - p. 517 48. Chapter 38 Genetic aspects of primary bone tumors - p. 531 49. Chapter 39 Markers for bone sarcomas - p. 543 50. Chapter 40 Molecular pathology of osteosarcoma - p. 579 51. Chapter 41 Genomic and proteomic profiling of osteosarcoma - p. 591 52. Chapter 42 Ewing's sarcoma family of tumors - p. 605 53. Chapter 43 Molecular aspects of Ewing's sarcomas - p. 617 54. Chapter 44 Osteoclast-rich lesions of bone - p. 631 55. Chapter 45 Biology of cartilage tumor family - p. 649 56. Chapter 46 Imaging of bone sarcomas - p. 665 57. Chapter 47 Current therapeutic approaches of bone sarcomas - p. 689 58. Chapter 48 What is an adequate margin after bone tumor resection? - p. 697 59. Chapter 49 Regulated cell death and drug resistance in malignant bone tumors - p. 703 60. Chapter 50 Chondrosarcoma of bone - p. 717 61. Chapter 51 Radiation therapy for primary bone tumors - p. 727 62. Chapter 52 New therapeutic advances of bone sarcomas - p. 755 63. Chapter 53 The histopathology of skeletal metastases - p. 771 64. Chapter 54 Identification of new therapeutic targets of bone cancers by proteomic strategies - p. 783 65. Chapter 55 Interventional radiologic techniques in the management of bone tumors - p. 807 66. Chapter 56 Diagnosis of bone metastases in urological malignancies—an update - p. 827 67. Chapter 57 Mechanisms and management of bone cancer pain - p. 853 68. Chapter 58 Involvement of sympathetic nerves in bone metastasis - p. 863 69. Chapter 59 Pain control with palliative radiotherapy in patients with bone metastases - p. 871 70. Chapter 60 Palliative care for patients with bone metastases - p. 889 71. Chapter 61 Role of radiation therapy in patients with bone metastasis - p. 909 72. Chapter 62 Cellular and molecular actions of bisphosphonates - p. 921 73. Chapter 63 Bone-targeted agents and skeletal-related events in breast cancer patients with bone metastases - p. 943 74. Chapter 64 Bone metastases—current status of bone-targeted treatments - p. 957 75. Chapter 65 Therapies of bone metastases in castration-resistant prostate cancer - p. 967 76. Chapter 66 Targeted radionuclide therapy in bone cancer - p. 977 77. Chapter 67 The effects of anticancer therapies on bone metastases in breast cancer - p. 987 78. Chapter 68 Biological relationship between bone and myeloma cells - p. 1005 79. Chapter 69 Recent therapeutic approaches in myeloma - p. 1019 80. Index - p. 1031
Bone Cancer: Bone Sarcomas and Bone Metastases - From Bench to Bedside, Third Edition comprehensively investigates key discoveries in the field of bone biology. New aspects of bone cancer biology are treated in new chapters covering exosomes, autophagy, and metabolism. These have led to the development of entirely new areas for investigation, such as therapies which combine surgery and biological approaches.
The Third Edition expands on the original overview of bone cancer development (physiology and pathophysiology), with 40% new material. Each chapter has been written by internationally recognized specialists on the bone cancer microenvironment, bone metastases, osteoclast biology in bone cancer, proteomics, bone niche, circulating tumor cells, and clinical trials.
Given the global prevalence of breast and prostate cancers, knowledge of bone biology has become essential for everyone within the medical and cancer research communities. Bone Cancer: Bone Sarcomas and Bone Metastases - From Bench to Bedside continues to offer the only translational reference to cover all aspects of primary bone cancer and bone metastases. This revision opens the door to myeloma with two short chapters dedicated to this bone-associated disease.
1. Bone Cancer - p. iii 2. Cover - p. iii 3. Title Page - p. iii 4. Copyright Page - p. iv 5. Table of Contents - p. iv 6. Contributors - p. xvii 7. Foreword I - p. xxiii 8. Foreword II - p. xxv 9. Foreword III - p. xxvii 10. Preface - p. xxix 11. Chapter 1 Cancer - p. 5 12. Chapter 2 Epidemiology of primary bone tumors and economical aspects of bone metastases - p. 17 13. Chapter 3 Mammalian models of bone sarcomas - p. 27 14. Chapter 4 In vivo models used in studies of bone metastases - p. 35 15. Chapter 5 Zebrafish models for studying bone tumors - p. 55 16. Chapter 6 Use of machine learning in bone cancers - p. 67 17. Chapter 7 Artificial intelligence for bone cancer imaging - p. 75 18. Chapter 8 Technical aspects - p. 93 19. Chapter 9 Bone niche and bone metastases - p. 107 20. Chapter 10 Bone, a fertile soil for tumor development - p. 121 21. Chapter 11 Osteomimicry - p. 129 22. Chapter 12 The role of mesenchymal stem cells in bone cancer - p. 145 23. Chapter 13 Technical approaches for studying the communications between osteocytes and cancer cells - p. 157 24. Chapter 14 Osteocytes and bone tumor niche - p. 171 25. Chapter 15 Immune functions of osteoclasts - p. 179 26. Chapter 16 The immune environment of bone sarcomas - p. 189 27. Chapter 17 Macrophages and pathophysiology of bone cancers - p. 205 28. Chapter 18 Growth factors, cytokines, and pediatric malignant primary bones tumors - p. 221 29. Chapter 19 Effects of NF-κB manipulation on cancer-associated bone disease - p. 241 30. Chapter 20 Transforming growth factor-β and its signaling pathway in skeletal complications of malignancy - p. 253 31. Chapter 21 Extracellular vesicles, tumor growth, and the metastatic process - p. 275 32. Chapter 22 Connexin43 and development of primary bone tumors - p. 285 33. Chapter 23 Role of classical cannabinoid receptors in cancer-associated bone disease - p. 295 34. Chapter 24 Impact of the acid microenvironment on bone cancers - p. 305 35. Chapter 25 Hypoxia-inducible factor (HIF)–mediated effects of the hypoxic niche in bone cancer - p. 321 36. Chapter 26 Energy metabolism in bone tumors - p. 337 37. Chapter 27 EMT process in bone metastasis - p. 359 38. Chapter 28 Cancer stem cells and clonal evolution in bone sarcomas - p. 371 39. Chapter 29 Dormancy in cancer bone metastasis - p. 393 40. Chapter 30 Bone remodeling markers and bone cancer - p. 413 41. Chapter 31 Epigenetic heterogeneity in primary bone cancers - p. 431 42. Chapter 32 MicroRNA implication in therapeutic resistance and metastatic dissemination of bone-associated tumors - p. 447 43. Chapter 33 MicroRNAs and bone metastasis - p. 457 44. Chapter 34 Long noncoding RNA and bone sarcoma - p. 471 45. Chapter 35 Liquid biopsy in bone sarcomas and identification of new biomarkers - p. 487 46. Chapter 36 Disseminated tumor cells in bone marrow of cancer patients - p. 501 47. Chapter 37 Cytogenetics of bone tumors - p. 517 48. Chapter 38 Genetic aspects of primary bone tumors - p. 531 49. Chapter 39 Markers for bone sarcomas - p. 543 50. Chapter 40 Molecular pathology of osteosarcoma - p. 579 51. Chapter 41 Genomic and proteomic profiling of osteosarcoma - p. 591 52. Chapter 42 Ewing's sarcoma family of tumors - p. 605 53. Chapter 43 Molecular aspects of Ewing's sarcomas - p. 617 54. Chapter 44 Osteoclast-rich lesions of bone - p. 631 55. Chapter 45 Biology of cartilage tumor family - p. 649 56. Chapter 46 Imaging of bone sarcomas - p. 665 57. Chapter 47 Current therapeutic approaches of bone sarcomas - p. 689 58. Chapter 48 What is an adequate margin after bone tumor resection? - p. 697 59. Chapter 49 Regulated cell death and drug resistance in malignant bone tumors - p. 703 60. Chapter 50 Chondrosarcoma of bone - p. 717 61. Chapter 51 Radiation therapy for primary bone tumors - p. 727 62. Chapter 52 New therapeutic advances of bone sarcomas - p. 755 63. Chapter 53 The histopathology of skeletal metastases - p. 771 64. Chapter 54 Identification of new therapeutic targets of bone cancers by proteomic strategies - p. 783 65. Chapter 55 Interventional radiologic techniques in the management of bone tumors - p. 807 66. Chapter 56 Diagnosis of bone metastases in urological malignancies—an update - p. 827 67. Chapter 57 Mechanisms and management of bone cancer pain - p. 853 68. Chapter 58 Involvement of sympathetic nerves in bone metastasis - p. 863 69. Chapter 59 Pain control with palliative radiotherapy in patients with bone metastases - p. 871 70. Chapter 60 Palliative care for patients with bone metastases - p. 889 71. Chapter 61 Role of radiation therapy in patients with bone metastasis - p. 909 72. Chapter 62 Cellular and molecular actions of bisphosphonates - p. 921 73. Chapter 63 Bone-targeted agents and skeletal-related events in breast cancer patients with bone metastases - p. 943 74. Chapter 64 Bone metastases—current status of bone-targeted treatments - p. 957 75. Chapter 65 Therapies of bone metastases in castration-resistant prostate cancer - p. 967 76. Chapter 66 Targeted radionuclide therapy in bone cancer - p. 977 77. Chapter 67 The effects of anticancer therapies on bone metastases in breast cancer - p. 987 78. Chapter 68 Biological relationship between bone and myeloma cells - p. 1005 79. Chapter 69 Recent therapeutic approaches in myeloma - p. 1019 80. Index - p. 1031
